Therapeutic Efficacy of telbivudine with phentolamine on patients with chronic severe hepatits B

Zhang WeiWei; Yuan XueHua; Tan HuaBing; Zhan GuoQing; Li RuGui; Du WeiXing

Issue 6

Jun. 2009

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2009 > 25(6): 418-419

PDF( 96 KB)

替比夫定联合酚妥拉明治疗慢性乙型重型肝炎的临床研究

Published Date: 2009-06-20

Abstract

Abstract

Objective To study the efficacy of telbivudine combined with phentolamine on chronic severe hepatits B patients.Methods 60 patients were randomly divided into two groups.The treatment group (n=30) were treated with telbivudine and phentolamine, while the control group (n=30) were treated with Yinzhihuang.Additionally, both groups were given supportive symptomatic therapy.Serum total bilirubin (TBIL) , PTA and HBV DNA were analyzed.Results TBIL in treatment group was decreased significantly after 4 weeks of therapy (p<0.05) .PTA and clinical conditions of the patients in the treatment group were significantly improved after 6 weeks of treatment (p<0.05) .The total treatment efficacy was found to be 70%.The level of HBV DNA in treatment group was significantly decreased compared with that of the control group (p<0.05) .Conclusion Telbivudine combined with phentolamine has a better effect on chronic severe hepatitis B patients.
- telbivudine,
- phentolamine,
- severe hepatitis,
- therapy

FullText(HTML)

References(8)

References

[1]中华医学会.病毒性肝炎防治方案[J].中华肝脏病杂志, 2000, 8 (6) ∶326.

[2]徐君, 张园海.拉米夫定治疗慢性乙型重型肝炎近期疗效观察[J].实用肝脏病杂志, 2004, 7 (4) ∶214-216.

[3]Villeneu JP, Condreay LD, Willems B, et al.Lamivudine treatment for decompensated cirrhosis resul-ting from chronic hepatitis B[J].Hepatology, 2000, 31 (1) ∶207-210.

[4]Yoshiba M.Recent advances in the treatment of fulminant hepatitisB[J].Nippon Rinsho, 2004, 62 (Suppl8) ∶280-283.

[5]梁月兰, 黄春新.治疗慢性乙肝新药——素比伏 (替比夫定片) [J].中南药学, 2007, 5 (3) ∶285-287.

[6]高寿征.病毒性肝炎防治研究[M].北京:北京出版社, 1993∶198.

[7]何桂香.小剂量肝素、立其丁联合治疗慢性淤胆型肝炎疗效观察[J].临床肝胆病杂志, 2003, 19 (1) ∶37-38.

[8]任安吉, 邱磷安, 林赛金, 等.酚妥拉明治疗重型肝炎35例[J].中西医结合肝病杂志, 1999, 9 (2) ∶65-66.

Relative Articles

[1]	Genes｜Identification of liver fibrosis-related microRNAs in human primary hepatic stellate cells using high-throughput sequencing[J]. Journal of Clinical Hepatology, 2023, 39(2): 283-283. doi: 10.3969/j.issn.1001-5256.2023.02.gwjpwzjj1
[2]	Journal of Hepatology｜Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated[J]. Journal of Clinical Hepatology, 2023, 39(2): 407-407. doi: 10.3969/j.issn.1001-5256.2023.02.gwjpwzjj2
[3]	Suriguga LU, Ting LIU, Dandan ZHU, Sijia YU, Liqing LU, Junjie DING. Research advances in hepatic fibrosis related signal pathways and anti-hepatic fibrosis drugs[J]. Journal of Clinical Hepatology, 2022, 38(5): 1161-1164. doi: 10.3969/j.issn.1001-5256.2022.05.039
[4]	Nannan QIAN, Lulu TANG, Taohua WEI, Yue YANG, Wenjie HAO, Wenming YANG. Role and mechanism of exosome non-coding RNA in liver fibrosis[J]. Journal of Clinical Hepatology, 2021, 37(10): 2429-2434. doi: 10.3969/j.issn.1001-5256.2021.10.036
[5]	Zhang ShiWan, Yu XueQin, Chen Fang, Mei YiHan, Mei XiaoPing. Biological characteristics of exosome microRNA and its role in the development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 2083-2086. doi: 10.3969/j.issn.1001-5256.2020.09.039
[6]	LU NenYuan, ZHONG FangFei, DENG QingMei, YANG YanQi, ZHENG Yang, ZHAO TieJian, LIANG TianJian. Regulatory effect of long non-coding RNAs on liver fibrosis[J]. Journal of Clinical Hepatology, 2020, 36(12): 2811-2814. doi: 10.3969/j.issn.1001-5256.2020.12.035
[7]	Zhu Hui, Ping Jian, Xu LieMing. Role of the nuclear factor-kappa B signaling pathway on the progress of hepatic fibrosis and the anti-fibrotic mechanism of traditional Chinese medicine[J]. Journal of Clinical Hepatology, 2018, 34(4): 858-861. doi: 10.3969/j.issn.1001-5256.2018.04.035
[8]	Li PingYing, Yang YongGeng, Lu LunGen, Zhu ZhiYong, Wang YaPing, Ma YingCai. Value of microRNAs in diagnosis of chronic hepatitis B-related liver fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(12): 2412-2415. doi: 10.3969/j.issn.1001-5256.2017.12.036
[9]	Zhang LiFen, Yu HongYu. Role of circulating microRNAs in development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2016, 32(10): 2001-2003. doi: 10.3969/j.issn.1001-5256.2016.10.042
[10]	Wang QingLan, Tao YanYan, Lu: Jing, Liu Ping, Liu ChengHai. Antifibrotic mechanism of Fuzheng Huayu prescription by regulation of the differential expression of microRNAs in mouse liver[J]. Journal of Clinical Hepatology, 2016, 32(3): 503-508. doi: 10.3969/j.issn.1001-5256.2016.03.022
[11]	Yang Li, Feng AiDong, Zheng HaoJie, Dai ErHei. Effects of Ruangan Huajian granules on mRNA expression of MMP- 13 and TIMP- 1 in liver tissue among C57 mice with hepatic fibrosis[J]. Journal of Clinical Hepatology, 2014, 30(4): 340-343. doi: 10.3969/j.issn.1001-5256.2014.04.013
[12]	Guo JinSheng. Recent perspectives on mechanisms of liver fibrogenesis: microRNA and cell autophagy [J]. Journal of Clinical Hepatology, 2013, 29(5): 324-326.
[13]	Li BinBin, Ming Jian, Chen DaGui, Xu MiDie, Yan HongZhu, Zhu Liang, Yu HongYu. Recent progress in understanding the role of microRNAs in hepatic stellate cell biology and liver fibrosis pathogenesis[J]. Journal of Clinical Hepatology, 2013, 29(5): 385-388.
[14]	Ni ZiHui, Xu Fang, Qin JunJie. Recent advances in understanding microRNAs involvement in liver fibrosis[J]. Journal of Clinical Hepatology, 2013, 29(3): 235-238.
[15]	Zheng SuJun, Xing XinYue, Wu JuShan, Wang ShiMei, Zhang Ying, Han YuanPing, Yu Hao, Chen Yu, Liu Mei, Duan ZhongPing. ShRNA targeted to rat Smad3 decreases the profibrosis role of TGFβ1 in HSC-T6 cells[J]. Journal of Clinical Hepatology, 2012, 28(4): 289-295.
[16]	Cai WeiMin. Some problems in anti-fibrotic therapies[J]. Journal of Clinical Hepatology, 2011, 27(3): 225-232.
[17]	Hao LiSen, Zhang XiaoLan. Signal transduction during hepatic stellate cell proliferation and possible therapeutic targets against hepatic fibrosis [J]. Journal of Clinical Hepatology, 2009, 25(1): 63-67.
[18]	Hu TaiHong, Jiang XiangHu, Jiang YueMing, Zhou Min, Xu Min, Zhu Rui, Yang Ling. Expression of NF-κB and ERK-1mRNA in rat with liver fibrosis[J]. Journal of Clinical Hepatology, 2009, 25(1): 23-25.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2195) PDF downloads(727)

替比夫定联合酚妥拉明治疗慢性乙型重型肝炎的临床研究

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

替比夫定联合酚妥拉明治疗慢性乙型重型肝炎的临床研究

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content